Physician profile
Johnny E Gomez
NPI 1699005538
$8,662.45
in general payments reported to CMS, 2019-2025
39 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,571 · 2022: $1,622 · 2023: $1,590 · 2024: $1,391 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,695.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,169.46 | 2021-2025 | |
| Lilly USA, LLC | $748.83 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.55 | 2021-2025 | Jardiance |
| Pfizer INC. | $518.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $384.94 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $296.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.92 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $222.94 | 2021-2024 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $218.74 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.79 | 2021-2025 | Xifaxan |
| Viiv Healthcare Company | $186.74 | 2023-2025 | Apretude |
| Exact Sciences Corporation | $185.52 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $172.55 | 2021-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company Ltd. | $169.50 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $156.01 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $136.07 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $133.02 | 2021-2023 | |
| Abbott Laboratories | $132.93 | 2021-2024 | Freestyle Libre |
| Amarin Pharma, INC. | $126.05 | 2021-2022 | |
| Radius Health, INC. | $117.39 | 2021-2025 | Tymlos |
| Amgen INC. | $105.05 | 2023-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.57 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $94.37 | 2023-2025 | Shingrix, Arexvy |
| Verity Pharmaceuticals INC. | $93.88 | 2024-2025 | Tlando |
| Almatica Pharma LLC | $91.11 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Janssen Pharmaceuticals, INC | $58.31 | 2022-2023 | Xarelto |
| Dexcom, INC. | $46.84 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $39.02 | 2021-2025 | Korlym |
| Esperion Therapeutics, INC. | $38.07 | 2024-2025 | Nexletol |
| Medtronic, INC. | $36.23 | 2022 | |
| Boston Scientific Corporation | $34.89 | 2025 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $34.64 | 2023-2024 | Austedo Xr |
| Currax Pharmaceuticals LLC | $32.77 | 2021-2022 | |
| Eisai INC. | $29.15 | 2021 | |
| Axsome Therapeutics, INC. | $27.98 | 2025 | Auvelity |
| Vivus LLC | $18.22 | 2023 | Qsymia |
| Ibsa Pharma INC. | $16.42 | 2024 | Licart, Tirosint |
| Exeltis, USA INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.